Biodiversity and BioPiracy: 5 Case Studies

These cases illustrate the tension between patent protection, traditional knowledge, and equitable ownership of biodiversity.

Case Study 1: The Turmeric Patent

The Turmeric Patent remains one of the most influential examples of traditional knowledge serving as prior art within the patent system. In 1995, the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 5,401,504 for the use of turmeric in wound healing. The patent was subsequently challenged by India's Council of Scientific and Industrial Research (CSIR), which produced documented evidence demonstrating that the claimed use had been part of traditional Indian medicinal knowledge for centuries.

The USPTO ultimately revoked the patent after determining that the claimed invention lacked novelty in light of the existing prior art. Beyond the revocation itself, the case established an important precedent for patent examination by recognizing that documented traditional knowledge can invalidate patents that merely claim existing knowledge in a different form. It also encouraged greater consideration of traditional knowledge databases during prior art searches and significantly influenced international discussions on preventing biopiracy within the patent system.

Case Study 2: The Neem Patent

The Neem Patent further highlighted the challenges of patenting innovations derived from traditional knowledge. A European patent granted to W.R. Grace & Co. and the United States Department of Agriculture concerning neem-based fungicidal formulations was challenged on the basis that the claimed invention reflected knowledge that had long existed within Indian agricultural and medicinal practices.

The European Patent Office eventually revoked the patent after finding that the claimed invention lacked novelty and inventive step. The significance of the dispute extended beyond the patent itself. It reinforced the principle that patents should reward genuine innovation rather than the rediscovery of existing traditional knowledge, while also encouraging patent offices to strengthen prior art examination involving traditional knowledge. The case continues to influence discussions on disclosure obligations, benefit-sharing, and the role of traditional knowledge in evaluating patentability.

Case Study 3: The Hoodia Cactus and the San People

The Hoodia cactus case is widely regarded as a landmark example of the importance of access and benefit-sharing (ABS) in biodiversity-based innovation. Researchers identified the appetite-suppressing properties of Hoodia gordonii, a plant traditionally used by the San people of Southern Africa, and subsequently patented the active compounds for potential pharmaceutical applications. Initially, neither the San communities nor their traditional knowledge was recognized during the commercialization process, leading to widespread criticism over the exclusion of Indigenous communities from the benefits arising from the research.

Following international attention and negotiations, a benefit-sharing agreement was concluded between the San people and the research institution involved, making the Hoodia case one of the earliest examples of formally recognizing Indigenous communities within the commercialization of biodiversity-derived innovations. The case significantly influenced discussions on prior informed consent (PIC) and equitable benefit-sharing, reinforcing the principles later reflected in the Nagoya Protocol. For the pharmaceutical industry, it underscored the importance of incorporating ethical sourcing, community engagement, and transparent access agreements into research and patent strategies involving traditional knowledge and genetic resources.

Case Study 4: The Rosy Periwinkle and Benefit-Sharing

The commercialization of the Rosy Periwinkle (Catharanthus roseus) has become a prominent example of the ethical and economic challenges surrounding biodiversity-based pharmaceutical innovation. Native to Madagascar, the plant became the source of the anti-cancer compounds vincristine and vinblastine, which were later developed into commercially successful medicines. Despite the substantial global economic value generated from these discoveries, Madagascar and the local communities associated with the plant did not receive a proportionate share of the resulting benefits.

Unlike disputes centered on patent validity, the Rosy Periwinkle case highlighted the broader issue of equitable benefit-sharing in the commercialization of biodiversity. It demonstrated that even where research and patent protection comply with legal requirements, significant ethical concerns may arise if provider countries and Indigenous communities are excluded from the economic benefits derived from their biological resources. The case continues to influence international policy discussions on biodiversity governance, emphasizing the need for stronger access and benefit-sharing mechanisms to ensure that innovation is accompanied by fairness, transparency, and recognition of source communities.

Case Study 5: Taxol (Paclitaxel) – Intellectual Property and Commercialization of Natural Products

The development of Taxol (paclitaxel) is widely recognized as a landmark example of how intellectual property can facilitate the commercialization of biodiversity-derived discoveries. Following the National Cancer Institute's (NCI) discovery and early development of paclitaxel, the technology was transferred to Bristol-Myers Squibb (BMS) through a Cooperative Research and Development Agreement (CRADA) and licensing arrangements. Rather than relying solely on the naturally occurring compound, the collaboration focused on developing patentable innovations relating to manufacturing processes, formulations, and methods of large-scale production, enabling the successful translation of publicly funded research into a commercially viable pharmaceutical product.

The case demonstrated that the greatest patent value often lies in innovative methods of production, formulation, and commercialization rather than in naturally occurring compounds themselves. It highlighted the importance of patent licensing, technology transfer, and public-private partnerships in converting biodiversity-based research into commercial innovation, while reinforcing the need for well-structured patent strategies for natural product-derived inventions.

Collectively, these cases demonstrate that disputes surrounding biodiversity extend beyond patent validity to broader issues of ownership, benefit-sharing, traditional knowledge, and the evolving role of intellectual property in governing biological resources.

Ethical Concerns Beyond Patent Law

The controversy surrounding biodiversity extends beyond legal ownership.

Many Indigenous communities oppose the treatment of biodiversity solely as an economic resource. Concerns frequently raised include:

• commercialization of living organisms;

• patenting of plants, microorganisms, and biological materials that were historically shared freely;

• exclusion of Indigenous communities from decision-making processes;

• absence of prior consent before accessing biological resources; and

• unequal distribution of economic benefits generated from biodiversity.

These ethical concerns have contributed to widespread allegations of biopiracy and have led to protests against numerous bioprospecting projects. Although no entity has been officially prosecuted for biopiracy under the Convention on Biological Diversity, public opposition has resulted in several proposed projects being abandoned. The controversies also encouraged many pharmaceutical companies to shift from natural-resource-based research toward synthetic approaches such as combinatorial chemistry, partly to avoid the legal and ethical complexities associated with biodiversity access.